EU/3/19/2186

About

On 25 July 2019, orphan designation EU/3/19/2186 was granted by the European Commission to Takeda Pharma A/S, Denmark, for pevonedistat for the treatment of acute myeloid leukaemia.

The sponsor’s address was updated in August 2020.

Key facts

Active substance
Pevonedistat
Disease / condition
Treatment of acute myeloid leukaemia
Date of first decision
25/07/2019
Outcome
Positive
EU designation number
EU/3/19/2186

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Takeda Pharma A/S
Delta Park 45
2665 Vallensbaek Strand
Hovedstaden
Danmark
Tel: +45 4677 1111
E-mail: kristina.stovring@takeda.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating